LOBO EV Technologies Ltd. Announces Strategic Collaboration with Roundtree Lab, LLC to Manufacture Advanced E-Hospital Beds
LOBO EV Technologies (Nasdaq: LOBO) has announced a strategic collaboration with Roundtree Lab to manufacture smart electric medical transport beds, marking LOBO's entry into the healthcare equipment market. The partnership combines LOBO's expertise in connectivity and multimedia systems with Roundtree's AI-driven bed technology.
Under the letter of intent, LOBO will serve as the Original Equipment Manufacturer (OEM) for Roundtree's AI-powered medical transport beds, utilizing Roundtree's patents and licenses. The collaboration aims to leverage Roundtree's U.S. hospital relationships for market expansion. The partnership is projected to generate over $10 million in revenue in 2025, subject to LOBO's delivery performance and manufacturing capabilities.
LOBO EV Technologies (Nasdaq: LOBO) ha annunciato una collaborazione strategica con Roundtree Lab per la produzione di letti di trasporto medico elettrici intelligenti, segnando l'ingresso di LOBO nel mercato delle attrezzature sanitarie. Il partenariato combina l'expertise di LOBO in connettività e sistemi multimediali con la tecnologia dei letti basata su intelligenza artificiale di Roundtree.
Ai sensi della lettera di intenti, LOBO fungerà da Costruttore di Originale Attrezzatura (OEM) per i letti di trasporto medico alimentati da AI di Roundtree, utilizzando i brevetti e le licenze di Roundtree. La collaborazione mira a sfruttare le relazioni di Roundtree con gli ospedali negli Stati Uniti per l'espansione del mercato. Si prevede che il partenariato generi oltre $10 milioni di entrate nel 2025, soggetto alla performance di consegna e alle capacità produttive di LOBO.
LOBO EV Technologies (Nasdaq: LOBO) ha anunciado una colaboración estratégica con Roundtree Lab para fabricar camas de transporte médico eléctricas inteligentes, marcando la entrada de LOBO en el mercado de equipos de salud. La asociación combina la experiencia de LOBO en conectividad y sistemas multimedia con la tecnología de camas impulsada por IA de Roundtree.
De acuerdo con la carta de intenciones, LOBO actuará como Fabricante de Equipos Originales (OEM) para las camas de transporte médico impulsadas por IA de Roundtree, utilizando las patentes y licencias de Roundtree. La colaboración tiene como objetivo aprovechar las relaciones de Roundtree con hospitales en EE. UU. para la expansión del mercado. Se proyecta que la asociación genere más de $10 millones en ingresos en 2025, sujeta al desempeño de entrega y a las capacidades de fabricación de LOBO.
LOBO EV Technologies (Nasdaq: LOBO)가 Roundtree Lab과의 전략적 협력을 발표하였습니다. 이 협력은 스마트 전기 의료 이송 침대를 제조하며, LOBO가 의료 기기 시장에 진입하는 계기가 됩니다. 이 파트너십은 LOBO의 연결성과 멀티미디어 시스템 전문성과 Roundtree의 AI 기반 침대 기술을 결합합니다.
청약서에 따라 LOBO는 Roundtree의 AI 기반 의료 이송 침대에 대한 원래 장비 제조업체 (OEM)로서 활동하며, Roundtree의 특허와 라이센스를 활용할 것입니다. 이 협력은 시장 확장을 위해 Roundtree의 미국 병원 관계를 활용하는 것을 목표로 합니다. 이 파트너십은 LOBO의 납품 성과 및 제조 능력에 따라 2025년까지 1천만 달러 이상의 수익을 창출할 것으로 예상됩니다.
LOBO EV Technologies (Nasdaq: LOBO) a annoncé une collaboration stratégique avec Roundtree Lab pour fabriquer des lits de transport médical électriques intelligents, marquant l'entrée de LOBO sur le marché des équipements de santé. Ce partenariat allie l'expertise de LOBO en connectivité et systèmes multimédias à la technologie de lit alimentée par IA de Roundtree.
Conformément à la lettre d'intention, LOBO agira en tant que Fabricant d'Équipements Originaux (OEM) pour les lits de transport médical alimentés par IA de Roundtree, utilisant les brevets et licences de Roundtree. La collaboration vise à exploiter les relations de Roundtree avec les hôpitaux américains pour l'expansion du marché. Le partenariat devrait générer plus de 10 millions de dollars de revenus en 2025, sous réserve de la performance de livraison et des capacités de fabrication de LOBO.
LOBO EV Technologies (Nasdaq: LOBO) hat eine strategische Zusammenarbeit mit Roundtree Lab angekündigt, um intelligente elektrische medizinische Transportbetten herzustellen, was den Einstieg von LOBO in den Gesundheitsgerätemarkt markiert. Die Partnerschaft vereint LOBOs Expertise in Konnektivität und Multimedia-Systemen mit Roundtrees KI-gesteuerter Bettechnologie.
Laut dem Absichtserklärung wird LOBO als Original Equipment Manufacturer (OEM) für Roundtrees KI-gestützte medizinische Transportbetten fungieren und dabei Roundtrees Patente und Lizenzen nutzen. Die Zusammenarbeit zielt darauf ab, Roundtrees Beziehungen zu US-Krankenhäusern für die Markterweiterung zu nutzen. Es wird erwartet, dass die Partnerschaft bis 2025 über 10 Millionen Dollar Umsatz generiert, abhängig von LOBOs Lieferleistung und Produktionskapazitäten.
- Projected revenue of over $10 million in 2025 from the new partnership
- Market diversification into healthcare equipment sector
- Access to U.S. healthcare market through Roundtree's existing relationships
- Leveraging existing manufacturing capabilities for new product line
- Revenue projections are contingent on meeting quality and manufacturing requirements
- Partnership currently based on letter of intent, pending definitive agreement
Insights
This strategic partnership represents a calculated pivot into the lucrative healthcare equipment sector, marking a significant expansion beyond LOBO's core electric vehicle business. The projected
From a manufacturing perspective, there are natural synergies between LOBO's existing capabilities in electric mobility systems and the requirements for advanced medical transport beds:
- Electric drive systems expertise can be adapted for bed movement mechanisms
- Experience with connectivity and multimedia systems aligns well with smart hospital equipment needs
- Existing quality control systems for vehicle safety can be repurposed for medical device standards
However, investors should consider several critical factors:
- Medical device manufacturing requires strict FDA compliance and certification, which could delay revenue realization
- The transition from vehicle to medical equipment production may require significant retooling and staff training
- Competition from established medical equipment manufacturers could impact market penetration
- The deal is currently at the LOI stage, with final terms and conditions still to be negotiated
The partnership with Roundtree provides LOBO access to valuable U.S. healthcare market relationships, potentially accelerating sales growth. However, success will heavily depend on LOBO's ability to meet stringent healthcare equipment quality standards and Roundtree's effectiveness in leveraging its hospital relationships for sales conversion.
The smart hospital bed market represents a high-growth opportunity within healthcare technology, driven by increasing focus on patient safety, staff efficiency and data-driven care. LOBO's entry through Roundtree's established presence could be well-timed, but success isn't guaranteed.
Key market dynamics to consider:
- Smart hospital beds typically command premium pricing, with potential for higher margins than consumer electric vehicles
- Healthcare facilities' purchasing cycles are lengthy, often 12-18 months, which could impact revenue timing
- Market dominated by established players like Hill-Rom and Stryker, who have deep relationships with healthcare providers
- AI integration in medical equipment is still emerging, offering potential first-mover advantages
Critical success factors will include:
- Obtaining necessary FDA clearances and certifications
- Building credibility with healthcare procurement departments
- Developing robust post-sale service and support networks
- Ensuring seamless integration with existing hospital systems
While Roundtree's existing relationships provide a valuable entry point, LOBO must demonstrate its ability to meet healthcare industry's stringent quality and reliability requirements. The transition from consumer products to medical devices represents a significant operational and cultural shift that will require careful management.
WUXI, China, Jan. 22, 2025 (GLOBE NEWSWIRE) -- LOBO EV Technologies Ltd. (Nasdaq: LOBO) (“LOBO” or the “Company”), an innovative e-bicycle, e-moped, e-tricycle, and electric off-highway four-wheeled shuttle designer, developer, manufacturer and seller, today announced that it entered into a letter of intent with Roundtree Lab, LLC (“Roundtree”), a Wyoming hospital equipment supplier, to manufacture smart electric medical transport beds. This partnership marks LOBO’s first foray into the healthcare equipment market, further underscoring the Company’s commitment to innovation and diversification. The parties expect to enter into a definitive agreement for this strategic collaboration.
The collaboration leverages LOBO’s extensive expertise in connectivity and multimedia interactive systems—capabilities historically applied to electric mobility design and manufacturing—and applies them to Roundtree’s advanced bed technology. By combining the patented AI solutions of Roundtree with LOBO’s state-of-the-art manufacturing processes, the two companies aim to improve patient care, safety, and efficiency within healthcare facilities.
Key Highlights of the Collaboration
- OEM Manufacturing Agreement
- LOBO will act as the Original Equipment Manufacturer (OEM) for Roundtree’s AI-driven medical transport beds, utilizing Roundtree’s valuable patents and licenses.
- Market Expansion
- Roundtree’s relationships with U.S. hospitals will accelerate market penetration for these advanced transport beds across the United States.
- Revenue Potential
- The partnership is projected to generate more than
$10 million in revenue in 2025, contingent on LOBO’s consistent delivery of high-quality products and its proven manufacturing capabilities.
- The partnership is projected to generate more than
Management Commentary
Huajian Xu, CEO of LOBO, commented:
“We are thrilled to join forces with Roundtree Lab to deliver AI-powered medical transport beds to the U.S. healthcare market. This collaboration underscores our dedication to creating cutting-edge products that offer exceptional value and user experience—whether on the road or in a hospital setting.”
Gordon Franklin, CEO of Roundtree Lab, added:
“LOBO’s proven manufacturing prowess and commitment to technology innovation make them the ideal partner. We believe our patented AI platform, combined with LOBO’s top-tier production, will raise the bar for patient care and operational efficiency in healthcare facilities.”
About LOBO EV Technologies Ltd.
LOBO is an innovative designer, developer, manufacturer and seller of e-bicycles, e-mopeds, e-tricycles, and electric off-highway four-wheeled shuttles such as golf carts and mobility scooters for the elderly and disabled persons. LOBO also provides automobile information and entertainment software development and design services to customers. Leveraging its cutting-edge technologies in connectivity, multimedia interactive systems and artificial intelligence, LOBO re-defines and develops its products in order to provide users with convenient, affordable and pleasant driving experiences. For more information, visit: https://www.loboebike.com and https://loboai.com. Any information displayed on, or that can be accessed through, our website or any other website or any social media is not a part of this press release.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) as well as Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended, that are intended to be covered by the safe harbor created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect,” “may,” “will,” “should,” “would,” “could,” “seek,” “intend,” “plan,” “goal,” “project,” “estimate,” “anticipate,” “strategy,” “future,” “likely” or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the expected closing date of the public offering and the Company’s strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements. Such forward-looking statements are subject to risk and uncertainties, including, but not limited to, those described in “Risk Factors,” “Operating and Financial Review and Prospects,” “Cautionary Note Regarding Forward-Looking Statements” in the Annual Report on Form 20-F filed with the SEC (File No. 333-270499) on April 30, 2024. LOBO undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events except as required by law. You should read this press release with the understanding that our actual future results may be materially different from what we expect.
Contact:
For more information, contact:
Zane Xu
IR Manager
ir@loboai.com
FAQ
What is the projected revenue for LOBO's partnership with Roundtree Lab in 2025?
What will LOBO manufacture under the Roundtree Lab partnership?
How will LOBO (NASDAQ: LOBO) enter the healthcare equipment market?
What is the current status of LOBO's agreement with Roundtree Lab?
How will LOBO's partnership with Roundtree Lab expand market reach?
